Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | $6,539.0M | $6,905.0M | $7,949.0M | $6,781.0M | $8,964.0M | $9,982.0M | $11.5B | $11.0B | $11.5B | $10.9B | $11.1B | $8,977.0M | $8,268.0M | $8,629.0M | $8,169.0M | $9,086.0M | $10.2B | $26.9B | $9,197.0M | $9,769.0M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Novartis AG's last 12-month Operating Income is $13.8B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Novartis AG's Operating Income growth was 45.1%. The average annual Operating Income growth rates for Novartis AG have been 11.9% over the past three years, 10.0% over the past five years.
Over the last year, Novartis AG's Operating Income growth was 45.1%, which is higher than industry growth of 0.0%. It indicates that Novartis AG's Operating Income growth is Good.